arsenic trioxide has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farrell, A; Martin, M; Miodragović, Ð; O'Halloran, TV; Qiang, W; Ren, J; Sattar Waxali, Z; Vitnik, V; Vitnik, Ž; Yang, Y | 1 |
| An, H; Bae, I; Heo, JS; Hong, E; Kim, P; Kim, SJ; Lee, J; Lee, S; Lian, Z; Ooshima, A; Pang, K; Park, H; Park, J; Park, KS; Park, Y; Son, M; Wu, Z; Yang, KM | 1 |
| Jiang, F; Li, Y; Li, Z; Si, L; Zhang, Z | 1 |
| Chan, R; Feddock, JM; Jyoti, A; Langner, UW; Nagarajan, R; O'Halloran, TV; Sethi, P; Swindell, EP; Upreti, M | 1 |
| Chan, R; Evers, BM; Feddock, JM; Johnson, SE; Jyoti, A; Napier, D; O'Halloran, TV; Sethi, P; Swindell, EP; Upreti, M; Weiss, HL | 1 |
5 other study(ies) available for arsenic trioxide and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Iodide Analogs of Arsenoplatins-Potential Drug Candidates for Triple Negative Breast Cancers.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance; Drug Therapy, Combination; Humans; Iodides; Molecular Conformation; Pharmaceutical Preparations; Spatial Analysis; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2021 |
Tetraarsenic hexoxide enhances generation of mitochondrial ROS to promote pyroptosis by inducing the activation of caspase-3/GSDME in triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Caspase 3; Cell Line, Tumor; Enzyme Activation; Female; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mitochondria; Oxidative Stress; Phosphorylation; Pyroptosis; Reactive Oxygen Species; Receptors, Estrogen; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms | 2021 |
Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells.
Topics: Arsenic Trioxide; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Female; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; NF-kappa B; Oncogene Protein p65(gag-jun); Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2019 |
3D tumor tissue analogs and their orthotopic implants for understanding tumor-targeting of microenvironment-responsive nanosized chemotherapy and radiation.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast; Cisplatin; Coculture Techniques; Disease Models, Animal; Drug Delivery Systems; Endothelial Cells; Female; Fibroblasts; Galectin 1; Mice; Mice, Nude; Nanoparticles; Oxides; Spheroids, Cellular; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Tumor Microenvironment | 2015 |
Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cells, Cultured; Chemoradiotherapy; Cisplatin; Female; Galectin 1; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cells; Mice; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Oxides; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays; Young Adult | 2016 |